Zymogenetics, Inc.

Merck Serono S. a.

Ares Trading S.a.

Claudia Pena Rossi

Jane A Gross

Kirk P Van Ness

Sharon J Busby

Wayne J Wallis

Alisa M Littau

Ivan Nestorov

Hans Otto Lennart Graffner

Orestis Papasouliotis

Alain Munafo

Rafael A Ponce, Jr

Linda Zuckerman

Jennifer Visich

Matthew S Holdren

Claudio Soto Jara

Jr Ponce Rafael A

Jr Rafael A Ponce

The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and immunosuppressants for the treatment of autoimmune diseases. One preferred method is where the BLyS and/or APRIL antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment thereof, a BAFF-R-Fc-fusion protein comprising the extracellular domain of BAFF-R or a functional fragment thereof, or a BCMA-Fc-fusion protein comprising the extracellular domain of BCMA or a functional fragment thereof. In the methods of the present invention some of the immunosuppressive drugs contemplated include cyclophosphamide (CYC), azathioprine (AZA), cyclosporine A (CSA), or mycophenolate mofetil (MMF), although any drug that suppresses the immune system may be suitable. The methods of the present invention reduce the levels of various immunoglobulins in patients in need of such reduction, such as those suffering from autoimmune diseases.

Combination of BLyS and/or APRIL inhibition and immunosuppressants for treatment of autoimmune disease

Growing community of inventors

Geneva, Switzerland

Claudia Pena Rossi